Cargando…

Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole

Sixty-three postmenopausal women with large primary breast cancers were treated with neoadjuvant letrozole (2.5 mg daily) for 3 months. Tumour samples were taken at diagnosis and after 10–14 days and 3 months treatment. Immunohistochemical staining for Ki67, oestrogen receptor (ER) and progesterone...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miller, W R, White, S, Dixon, J M, Murray, J, Renshaw, L, Anderson, T J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2006
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361236/ https://www.ncbi.nlm.nih.gov/pubmed/16538221 http://dx.doi.org/10.1038/sj.bjc.6603001

Ejemplares similares

Oestrogen receptor β and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment
por: Miller, W R, et al.
Publicado: (2006)

Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer
por: Torrisi, R, et al.
Publicado: (2007)

Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy
por: Fujii, Takeo, et al.
Publicado: (2017)

Effect of the chemokine receptor CXCR7 on proliferation of carcinoma cells in vitro and in vivo
por: Meijer, J, et al.
Publicado: (2008)

Tissue biomarkers of breast cancer and their association with conventional pathologic features
por: Chung, L, et al.
Publicado: (2013)

Proliferation marker securin identifies favourable outcome in invasive ductal breast cancer
por: Talvinen, K, et al.
Publicado: (2008)

Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer
por: Seo, A N, et al.
Publicado: (2013)

The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer
por: Mohammed, Z M A, et al.
Publicado: (2013)

Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium
por: Adams, R L, et al.
Publicado: (2005)

Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance
por: Palmieri, C, et al.
Publicado: (2013)

Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer
por: Ohotski, J, et al.
Publicado: (2012)

Inhibition of triple-negative and Herceptin-resistant breast cancer cell proliferation and migration by Annexin A2 antibodies
por: Chaudhary, P, et al.
Publicado: (2014)

Pregnane X receptor suppresses proliferation and tumourigenicity of colon cancer cells
por: Ouyang, N, et al.
Publicado: (2010)

Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology
por: Ursin, G, et al.
Publicado: (2005)

A role for nucleotides in support of breast cancer angiogenesis: heterologous receptor signalling
por: Yokdang, N, et al.
Publicado: (2011)

Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma
por: Zhang, G Y, et al.
Publicado: (2005)

Oestrogen receptors β1 and βcx have divergent roles in breast cancer survival and lymph node metastasis
por: Rosin, G, et al.
Publicado: (2014)

The in situ local immune response, tumour senescence and proliferation in colorectal cancer
por: Roxburgh, C S, et al.
Publicado: (2013)

Expression of oestrogen receptor-β in oestrogen receptor-α negative human breast tumours
por: Skliris, G P, et al.
Publicado: (2006)

Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer
por: West, N R, et al.
Publicado: (2013)

The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone
por: Campbell, Esther J, et al.
Publicado: (2016)

Tamoxifen resistance in early breast cancer: statistical modelling of tissue markers to improve risk prediction
por: Baneshi, M R, et al.
Publicado: (2010)

Lack of correlation of stem cell markers in breast cancer stem cells
por: Liu, Y, et al.
Publicado: (2014)

Effects of platelet-activating factor and its differential regulation by androgens and steroid hormones in prostate cancers
por: Xu, B, et al.
Publicado: (2013)

Serum oestrogen receptor α and β bioactivity are independently associated with breast cancer: a proof of principle study
por: Widschwendter, M, et al.
Publicado: (2009)

Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients
por: Innes, H E, et al.
Publicado: (2006)

Multivariate analysis of oestrogen receptor alpha, pS2, metallothionein and CD24 expression in invasive breast cancers
por: Surowiak, P, et al.
Publicado: (2006)

Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy
por: Nieto, Y, et al.
Publicado: (2007)

BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast
por: Millar, E K A, et al.
Publicado: (2009)

Cadherin-5: a biomarker for metastatic breast cancer with optimum efficacy in oestrogen receptor-positive breast cancers with vascular invasion
por: Fry, Simon A, et al.
Publicado: (2016)

K-ras mutation in the endometrium of tamoxifen-treated breast cancer patients, with a comparison of tamoxifen and toremifene
por: Hachisuga, T, et al.
Publicado: (2005)

Integrin β1 is required for the invasive behaviour but not proliferation of squamous cell carcinoma cells in vivo
por: Brockbank, E C, et al.
Publicado: (2005)

Slow proliferation as a biological feature of colorectal cancer metastasis
por: Anjomshoaa, A, et al.
Publicado: (2009)

Gut microbiota-derived propionate reduces cancer cell proliferation in the liver
por: Bindels, L B, et al.
Publicado: (2012)

ING1b-inducible microRNA203 inhibits cell proliferation
por: Chen, J, et al.
Publicado: (2013)

Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy
por: Manton, D J, et al.
Publicado: (2006)

Gene expression profile and response to trastuzumab–docetaxel-based treatment in breast carcinoma
por: Végran, F, et al.
Publicado: (2009)

‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
por: Pallis, A G, et al.
Publicado: (2007)

Increased microvascular proliferation is negatively correlated to tumour blood flow and is associated with unfavourable outcome in endometrial carcinomas
por: Haldorsen, I S, et al.
Publicado: (2014)

Changes in subcellular localisation of MI-ER1α, a novel oestrogen receptor-α interacting protein, is associated with breast cancer progression
por: McCarthy, P L, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_8ooq5ic2tvo379ftueqajp3ked